Nanwei Co., Ltd.’s 2025 Annual Performance Preliminary Loss Announcement
Securities code: 603880 Securities abbreviation: Nanwei Co., Ltd. Announcement number: 2026-007 Jiangsu Nanfang Weicai Pharmaceutical Co., Ltd.
2025 Annual Performance Preliminary Loss Announcement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
Jiangsu Nanfang Weisai Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) due to the annual operating business in 2025
Disclose a performance forecast when the following circumstances arise in terms of performance and financial status: The company's net profit in 2025 will be negative; The company estimates that the net profit attributable to the owners of the parent company in 2025 will be -80 million yuan, and the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be -82 million yuan.
1. Performance forecast for this period
(1) Performance forecast period
From January 1, 2025 to December 31, 2025.
(2) Performance forecast
According to preliminary calculations by the company's financial department, the net profit attributable to the owners of the parent company is expected to be -80 million yuan in 2025, indicating a loss.
It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses in 2025 will be -82 million yuan.
(3) The performance forecast for this period has not been audited by a certified public accountant.
2. Operating results and financial status for the same period last year
(1) Total profit: -200.8589 million yuan. Net profit attributable to owners of the parent company: -190.669 million yuan. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses: -187.7309 million yuan.
(2) Earnings per share: -0.66 yuan.
3. The main reasons for the expected loss in this period’s performance
During the reporting period, the company's wholly-owned subsidiary Anhui Nanwei Medical Supplies Co., Ltd.'s production and sales of nitrile gloves and other products were affected by the industry market environment. Production capacity was not fully released, and operating performance was poor. The fixed costs of related production lines were high, which had a significant adverse impact on the company's overall operating performance this year.
4. Risk warning
As of the disclosure date of this announcement, the company has no major uncertain factors that affect the accuracy of this performance forecast.
5. Other explanations
This performance forecast is the result of preliminary calculations by the company's financial department and has not been audited by a certified public accountant. The specific and accurate financial data is subject to the company's officially disclosed "2025 Annual Report". Investors are advised to make prudent decisions and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Jiangsu Southern Health Care Pharmaceutical Co., Ltd.
January 31, 2026